New Drug Trial Offers Hope for Patients with a Painful Muscle Condition

The New England Journal of Medicine posted about the trial on social media, flagging a new video summarising the research in partnership with the medical education account Dr Glaucomflecken. The full study is available to read free of charge through the journal.

Polymyalgia rheumatica (PMR) is a condition that causes pain, stiffness and aching, usually in the shoulders, neck, upper arms and hips. It most commonly affects people over 50, and according to the NHS, it tends to come on relatively quickly — sometimes over just a few days.

The REPLENISH trial looked at secukinumab, a drug that works by blocking a protein in the immune system called interleukin-17A. Researchers evaluated both how well it worked (its efficacy) and how safe it was for people with PMR.

So why does this matter? Current treatment for PMR relies heavily on corticosteroids (steroid tablets), which can cause side effects including bone thinning and raised blood sugar when used long-term. A drug that works differently could offer an alternative for patients who struggle with those effects.

The journal has not yet released detailed results in the social media post itself — the full findings are in the published study. The video summary, produced with Dr Glaucomflecken, is aimed at making the research accessible to a wider audience beyond specialist rheumatologists.

Anyone experiencing persistent muscle pain or stiffness, chiefly around the shoulders and hips, should speak to their GP rather than wait. PMR is treatable, and early diagnosis matters.

Key information

• For new or unexplained muscle pain lasting more than a few weeks, contact your GP
• For urgent medical advice, call NHS 111
• The full REPLENISH trial is published in the New England Journal of Medicine and is free to access